Pachydermoperiostosis: analysis of the connective tissue abnormality in one family.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMID 7962775)

Published in J Am Acad Dermatol on December 01, 1994

Authors

A Oikarinen1, R Palatsi, M Kylmäniemi, J Keski-Oja, J Risteli, M Kallioinen

Author Affiliations

1: Department of Dermatology, University of Oulu, Finland.

Articles by these authors

Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J Exp Med (1987) 4.35

Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium. J Cell Biol (1988) 4.34

Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest (1987) 2.74

Growth factors in the extracellular matrix. FASEB J (1997) 2.71

Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem (1990) 2.51

Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J Cell Biol (1986) 2.44

Latent transforming growth factor-beta binding proteins (LTBPs)--structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev (1999) 2.22

7-S collagen: characterization of an unusual basement membrane structure. Eur J Biochem (1980) 2.19

Dimeric character of fibronectin, a major cell surface-associated glycoprotein. Biochem Biophys Res Commun (1977) 2.18

Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J Cell Biol (1994) 2.15

Induction of fibroblast chemotaxis by fibronectin. Localization of the chemotactic region to a 140,000-molecular weight non-gelatin-binding fragment. J Exp Med (1981) 2.10

Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen. Lancet (1993) 2.09

Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J Biol Chem (1987) 2.05

Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell (2000) 2.01

Macromolecular structure of basement membrane collagens. FEBS Lett (1981) 1.96

Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr (1998) 1.94

Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation (1997) 1.93

Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int (2001) 1.88

The O75X adhesin of uropathogenic Escherichia coli is a type IV collagen-binding protein. Mol Microbiol (1989) 1.87

Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A (2001) 1.83

Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem (1996) 1.79

Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med (1989) 1.77

Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70

Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech (2001) 1.70

The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68

Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem (1991) 1.68

Transforming growth factors and control of neoplastic cell growth. J Cell Biochem (1987) 1.67

Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell (1976) 1.64

Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest (1994) 1.62

Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem (1995) 1.61

Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res (1993) 1.57

Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology (1990) 1.56

Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas. Arch Dermatol (2000) 1.56

Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res (1989) 1.55

Structural diversity and domain composition of a unique collagenous fragment (intima collagen) obtained from human placenta. Biochem J (1983) 1.55

Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol (1998) 1.53

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol (2004) 1.53

Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem (1992) 1.50

Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J (1996) 1.50

Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J (1998) 1.48

Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. Adv Cancer Res (1998) 1.48

Collagen metabolites in the prediction of response to GH therapy in short children. Eur J Endocrinol (1997) 1.40

Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer (1999) 1.38

Impaired migration and delayed differentiation of pancreatic islet cells in mice lacking EGF-receptors. Development (2000) 1.38

Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene (2000) 1.37

Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem (2000) 1.36

The cellular response to induction of the p21 c-Ha-ras oncoprotein includes stimulation of jun gene expression. EMBO J (1989) 1.35

Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem (1996) 1.35

Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer (1992) 1.34

Transforming growth factor beta alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res (1986) 1.32

Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. Int J Cancer (1982) 1.31

Murine sarcoma growth factors affect the growth and morphology of cultured mouse epithelial cells. J Cell Physiol (1980) 1.30

Direct association of fibronectin and actin molecules in vitro. J Cell Biol (1980) 1.28

Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med (2008) 1.28

Intracellular enzymes of collagen biosynthesis in rat liver as a function of age and in hepatic injury induced by dimethylnitrosamine. Purification of rat prolyl hydroxylase and comparison of changes in prolyl hydroxylase activity with changes in immunoreactive prolyl hydroxylase. Biochem J (1976) 1.27

Activities of prolyl hydroxylase, lysyl hydroxylase, collagen galactosyltransferase and collagen glucosyltransferase in the liver of rats with hepatic injury. Biochem J (1974) 1.25

Intracellular enzymes of collagen biosynthesis in rat liver as a function of age and in hepatic injury induced by dimethylnitrosamine. Changes in prolyl hydroxylase, lysyl hydroxylase, collagen galactosyltransferase and collagen glucosyltransferase activities. Biochem J (1976) 1.24

Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4. J Biol Chem (1998) 1.24

Fibroblast surface antigen (SF): molecular properties, distribution in vitro and in vivo, and altered expression in transformed cells. J Supramol Struct (1976) 1.23

Latent TGF-beta binding protein LTBP-1 contains three potential extracellular matrix interacting domains. J Cell Sci (2001) 1.23

Activation of paracrine TGF-beta1 signaling upon stimulation and degranulation of rat serosal mast cells: a novel function for chymase. FASEB J (2001) 1.22

Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease. Eur J Clin Invest (1985) 1.22

Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem (1996) 1.22

Interaction of viral envelope glycoproteins with fibronectin. Infect Immun (1983) 1.21

Synthesis of type I collagen in healing wounds in humans. Ann Surg (1991) 1.19

Transforming growth factor beta regulation of cell proliferation. J Cell Physiol Suppl (1987) 1.18

Distribution of a major surface-associated glycoprotein, fibronectin, in cultures of adherent cells. J Supramol Struct (1977) 1.18

Mononuclear cell subsets in the nickel-allergic reaction in vitro and in vivo. J Allergy Clin Immunol (1992) 1.17

Prolyl 3-hydroxylase: partial characterization of the enzyme from rat kidney cortex. Eur J Biochem (1977) 1.15

1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ (2000) 1.14

Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol (1996) 1.13

Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J (1990) 1.12

Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone (2000) 1.12

Independent promoters regulate the expression of two amino terminally distinct forms of latent transforming growth factor-beta binding protein-1 (LTBP-1) in a cell type-specific manner. J Biol Chem (1999) 1.12

Pericellular substrates of human mast cell tryptase: 72,000 dalton gelatinase and fibronectin. J Cell Biochem (1992) 1.12

In vivo biocompatibility evaluation of nickel-titanium shape memory metal alloy: muscle and perineural tissue responses and encapsule membrane thickness. J Biomed Mater Res (1998) 1.11

The cellular target for the plasminogen activator, urokinase, in human fibroblasts - 66 000 dalton protein. Biochim Biophys Acta (1982) 1.09

Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol (1998) 1.08

Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery (1990) 1.08

Partial purification and characterization of chick-embryo prolyl 3-hydroxylase. Biochem J (1979) 1.08

Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner (1994) 1.07

A new method to measure type I and III collagen synthesis in human skin in vivo: demonstration of decreased collagen synthesis after topical glucocorticoid treatment. J Invest Dermatol (1992) 1.07

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer (1995) 1.06

Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol (2001) 1.06

Collagen biosynthesis enzymes in serum and hepatic tissue in liver disease. I. Prolyl hydroxylase. Eur J Clin Invest (1979) 1.05

Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis (1993) 1.05

Analysis of extracellular matrix proteins in biological fluids. Methods Enzymol (1987) 1.04

Immunohistochemical study of type I collagen and type I pN-collagen in benign and malignant ovarian neoplasms. Cancer (1995) 1.04

Multiple miliary osteoma cutis is a distinct disease entity: four case reports and review of the literature. Br J Dermatol (2011) 1.04

Dose effects of transfected c-Ha-rasVal 12 oncogene in transformed cell clones. Exp Cell Res (1987) 1.04

Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer (1996) 1.03

Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br J Dermatol (1992) 1.03

Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res (2001) 1.02

Systemic glucocorticoids decrease the synthesis of type I and type III collagen in human skin in vivo, whereas isotretinoin treatment has little effect. Br J Dermatol (1994) 1.02

Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology (2001) 1.02

Gremlin localization and expression levels partially differentiate idiopathic interstitial pneumonia severity and subtype. J Pathol (2008) 1.02

Interaction of fibronectin with complement component C3. Scand J Immunol (1983) 1.01

Biochemical markers of bone metabolism. Ann Med (1993) 1.01